ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Wednesday, October 29, 2025

8:00AM-8:15AM
Abstract Number: LB19
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
(LB19–LB24) Late-Breaking Abstracts
8:15AM-8:30AM
Abstract Number: LB20
Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
(LB19–LB24) Late-Breaking Abstracts
8:30AM-8:45AM
Abstract Number: LB21
IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
(LB19–LB24) Late-Breaking Abstracts
8:45AM-9:00AM
Abstract Number: LB22
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
(LB19–LB24) Late-Breaking Abstracts
9:00AM-9:15AM
Abstract Number: LB23
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
(LB19–LB24) Late-Breaking Abstracts
9:15AM-9:30AM
Abstract Number: LB24
Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)
(LB19–LB24) Late-Breaking Abstracts
9:30AM-9:45AM
Abstract Number: 2645
Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries
Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)
9:30AM-9:45AM
Abstract Number: 2651
Development and Validation of the Scleroderma Clinical Trials Consortium Classification Criteria for Systemic Sclerosis Heart Involvement
Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)
9:30AM-9:45AM
Abstract Number: 2639
Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis
Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)
9:45AM-10:00AM
Abstract Number: 2652
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)
9:45AM-10:00AM
Abstract Number: 2646
DNA methylation-based clustering reveals clinically distinct subtypes of systemic lupus erythematosus
Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)
9:45AM-10:00AM
Abstract Number: 2640
Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)
10:00AM-10:15AM
Abstract Number: 2641
Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)
10:00AM-10:15AM
Abstract Number: 2653
First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes
Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)
10:00AM-10:15AM
Abstract Number: 2647
Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features
Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology